Eligibility for individual expanded access generally requires the following criteria to be met: - The patient has a serious or immediately life-threatening condition. - No comparable or satisfactory alternative therapy is available. - The potential patient benefit justifies the potential risks. - The use of the investigational product will not interfere with ongoing clinical trials.
